Brain metastases from solid tumors: disease outcome according to type of treatment and therapeutic resources of the treating center

BackgroundTo evaluate the therapeutic strategies commonly employed in the clinic for the management of brain metastases (BMs) and to correlate disease outcome with type of treatment and therapeutic resources available at the treating center.MethodsFour Cancer centres participated to the survey. Data were collected through a questionnaire filled in by one physician for each centre.ResultsClinical data regarding 290 cancer patients with BMs from solid tumors were collected. Median age was 59 and 59% of patients had ≤ 3 brain metastases. A local approach (surgery and stereotactic radiosurgery) was adopted in 31% of patients. The local approach demonstrated to be superior in terms of survival compared to the regional/systemic approach (whole brain radiotherapy and chemotherapy, p = <.0001 for survival at 2 years). In the multivariate analysis local treatment was an independent prognostic factor for survival. When patients were divided into 2 groups whether they were treated in centers where local approaches were available or not (group A vs group B respectively, 58% of patients with ≤ 3 BMs in both cohorts), more patients in group A received local strategies although no difference in time to brain progression at 1 year was observed between the two groups of patients.ConclusionsIn clinical practice, local strategies should be integrated in the management of brain metastases. Proper selection of patients who are candidate to local treatments is of crucial importance.

[1]  R. Rouzier,et al.  Breast cancer with synchronous metastases: trends in survival during a 14-year period. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Goldhirsch,et al.  High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  K Takakura,et al.  [Metastatic brain tumors]. , 1980, Rinsho hoshasen. Clinical radiography.

[4]  D. Kondziolka,et al.  The impact of whole-brain radiation therapy on the long-term control and morbidity of patients surviving more than one year after gamma knife radiosurgery for brain metastases. , 2005, International journal of radiation oncology, biology, physics.

[5]  J. Posner Brain metastases: 1995. A brief review , 1996, Journal of Neuro-Oncology.

[6]  P. Wen,et al.  Management of brain metastases. , 1999, Oncology.

[7]  C. L. La Porta Drug resistance in melanoma: new perspectives. , 2007, Current medicinal chemistry.

[8]  Roy A Patchell,et al.  The management of brain metastases. , 2003, Cancer treatment reviews.

[9]  P. Levendag,et al.  Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. , 1999, International journal of radiation oncology, biology, physics.

[10]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[11]  M. Rinaldi,et al.  Up‐front chemotherapy and radiation treatment in newly diagnosed nonsmall cell lung cancer with brain metastases , 2007, Cancer.

[12]  L Gaspar,et al.  Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. , 1997, International journal of radiation oncology, biology, physics.

[13]  Henry Brem,et al.  Central nervous system cancers. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.

[14]  F. Cappuzzo,et al.  Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). , 2003, Lung cancer.

[15]  W. Curran,et al.  Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  D. Carney Lung cancer--time to move on from chemotherapy. , 2002, The New England journal of medicine.

[17]  Ronald Brand,et al.  Treatment of single brain metastasis: Radiotherapy alone or combined with neurosurgery , 1993, Annals of neurology.

[18]  M. Mehta,et al.  Current management of brain metastases, with a focus on systemic options. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Roy A. Patcheil Metastatic brain tumors. , 1995 .

[20]  KyungMann Kim,et al.  Contrasting treatment‐specific survival using double‐robust estimators , 2012 .

[21]  P. Cornu,et al.  EFNS Guidelines on diagnosis and treatment of brain metastases: report of an EFNS Task Force , 2006, European journal of neurology.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  F. Cognetti,et al.  Dramatic Regression of Multiple Brain Metastases from Breast Cancer with Capecitabine: Another Arrow at the Bow? , 2006, Cancer investigation.

[24]  A. Howell,et al.  Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer , 2004, British Journal of Cancer.

[25]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[26]  Henry Brem,et al.  Central nervous system cancers: Clinical Practice Guidelines in Oncology. , 2005, Journal of the National Comprehensive Cancer Network : JNCCN.